{"product_id":"t-cell-lymphoblastic-lymphoma-of-the-breast-what-a-rare-cancer-study-found","title":"T-Cell Lymphoblastic Lymphoma of the Breast: What a Rare Cancer Study Found","description":"\u003cp\u003eThis retrospective study combined one new patient case with a systematic review of the medical literature. The study described T-cell lymphoblastic lymphoma (T-LBL) of the breast, an extremely rare and aggressive cancer. Across 11 female patients with a mean age of about 32 years, 5 had tumors in both breasts and 6 had tumors in one breast, and 10 of the 11 had cancer spread beyond the breast. Most patients (10 of 11) received chemotherapy, sometimes with radiation therapy and preventive treatment into the spinal fluid. The authors conclude that accurate diagnosis is essential and that future prospective studies are needed to improve diagnosis and treatment.\u003c\/p\u003e\n\n\u003ch1\u003eT-Cell Lymphoblastic Lymphoma of the Breast: What a Rare Cancer Study Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Is T-Cell Lymphoblastic Lymphoma?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-breast\"\u003eWhy the Breast Is an Unusual Site for This Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#case\"\u003eThe New Patient Case: A 45-Year-Old Woman\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#imaging\"\u003eImaging Findings: Ultrasound, Mammography, MRI, and PET-CT\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pathology\"\u003ePathology and Bone Marrow Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#literature\"\u003eWhat the Literature Review Found Across 11 Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#discussion\"\u003eDiscussion: Diagnosis, Biology, and Behavior of Breast T-LBL\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#molecular\"\u003eMolecular and Genetic Features\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Take-Home Points\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a review of 11 female patients with breast T-cell lymphoblastic lymphoma, 5 had tumors in both breasts and 6 in one breast.\u003c\/li\u003e\n\u003cli\u003eTen of the 11 reviewed patients had cancer spread beyond the breast, showing it is usually not confined to the breast at diagnosis.\u003c\/li\u003e\n\u003cli\u003eAccurate diagnosis requires a full panel of immunohistochemical markers; TdT and CD3 were positive in 9 breast lesions reviewed.\u003c\/li\u003e\n\u003cli\u003eTreatment in the reviewed cases centered on chemotherapy, with some patients also receiving radiotherapy and intrathecal prophylaxis.\u003c\/li\u003e\n\u003cli\u003eThe authors call for future prospective studies to improve diagnosis and treatment of this extremely rare cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Is T-Cell Lymphoblastic Lymphoma?\u003c\/h2\u003e\n\u003cp\u003eLymphoblastic lymphoma is a rare and aggressive subtype of non-Hodgkin's lymphoma (a group of cancers that start in the lymphatic system). It begins in precursor lymphoblastoid cells, which are early-stage immune cells at various points of development.\u003c\/p\u003e\n\u003cp\u003eDoctors divide lymphoblastic lymphoma into two lineages based on the type of cell involved: B-cell and T-cell. T-cell lymphoblastic lymphoma (T-LBL) makes up about 70% to 80% of these cases.\u003c\/p\u003e\n\u003cp\u003eT-LBL has a distinct pattern in the population. It mostly affects adolescents and young adults, and it is notably more common in males. The disease often appears as a rapidly growing mass in the mediastinum (the central chest area between the lungs), and it frequently involves lymph nodes.\u003c\/p\u003e\n\u003cp\u003ePrimary extranodal disease — meaning the cancer starts outside the lymph nodes, such as in the breast — is exceedingly rare.\u003c\/p\u003e\n\n\u003ch2 id=\"why-breast\"\u003eWhy the Breast Is an Unusual Site for This Cancer\u003c\/h2\u003e\n\u003cp\u003eOn a cellular level, T-LBL blasts (immature cancer cells) typically carry immature T-cell markers. The most consistent and characteristic markers are cytoplasmic cluster of differentiation 3 (CD3; also written cCD3), CD7, and terminal deoxynucleotidyl transferase (TdT).\u003c\/p\u003e\n\u003cp\u003eOther markers — CD1a, CD2, CD5, and CD4\/CD8 (which can appear as double-positive or double-negative) — are expressed variably. This variability reflects the stage of thymic differentiation (how far the cell has matured in the thymus, an organ in the chest where T cells develop).\u003c\/p\u003e\n\u003cp\u003eIt is also common to see co-expression of myeloid-associated markers CD13 or CD33. This immunophenotypic profile (the pattern of proteins on the cell surface) is crucial for distinguishing T-LBL from other mature T-cell lymphomas. This profile is also crucial for confirming that the cancer comes from precursor cells.\u003c\/p\u003e\n\u003cp\u003eT-LBL and T-cell acute lymphoblastic leukemia (T-ALL) share similar morphology (cell appearance), immunophenotype (marker pattern), and clinical behavior. Because of these similarities, the 2022 World Health Organization (WHO) classification regards them as a single biological entity that spans a disease spectrum.\u003c\/p\u003e\n\u003cp\u003eThe practical distinction between the two remains based on how much the bone marrow is involved. A blast proportion below 25% is classified as T-LBL, while 25% or higher defines T-ALL.\u003c\/p\u003e\n\u003cp\u003ePrimary involvement of the breast by lymphoblastic lymphoma is an exceptional clinical scenario. This article analyzes the clinical data of patients with T-LBL treated at the authors' hospital and at Shanghai Ruijin Hospital. The goal is to improve understanding of T-LBL in breast tissue.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Study\u003c\/h2\u003e\n\u003cp\u003eThe study had two parts: a detailed report of one patient case and a systematic review of the medical literature.\u003c\/p\u003e\n\u003cp\u003eFrom July 2023 to April 2024, Jiaxing Maternity and Child Health Care Hospital and Shanghai Ruijin Hospital worked together to diagnose and treat a single case of breast T-LBL.\u003c\/p\u003e\n\u003cp\u003eTo ensure the literature search was transparent and reproducible, the researchers searched multiple databases up to May 10, 2024. These databases included PubMed, Web of Science, Embase, Cochrane Library, China Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang, and Wipro.\u003c\/p\u003e\n\u003cp\u003eThe search strategy used Boolean operators (a method for combining search terms). The key terms were (\"T-cell lymphoblastic lymphoma\" OR \"T-LBL\") AND (\"breast\" OR \"mammary\") in English databases, along with their corresponding Chinese translations in Chinese databases.\u003c\/p\u003e\n\u003cp\u003eAdvanced filters restricted results by publication type, date range, and human studies. The selection criteria included case reports, clinical studies, and reviews relevant to breast T-cell lymphoblastic lymphoma.\u003c\/p\u003e\n\u003cp\u003eThe researchers excluded unrelated lymphoma types, studies without breast involvement, and duplicate publications. This methodology followed established systematic review practices to ensure a comprehensive and replicable search process.\u003c\/p\u003e\n\u003cp\u003eFor the identified cases, the inclusion criteria required patients with histopathologically confirmed T-LBL (confirmed by tissue examination) plus comprehensive clinical, imaging, and pathological documentation. The exclusion criteria removed T-ALL cases and literature lacking myelocentesis procedures (bone marrow sampling). Duplicate cases from identical authors, institutions, research entities, and databases were also omitted.\u003c\/p\u003e\n\n\u003ch2 id=\"case\"\u003eThe New Patient Case: A 45-Year-Old Woman\u003c\/h2\u003e\n\u003cp\u003eThe new patient was a 45-year-old woman. She discovered a walnut-sized lump in her left breast about two weeks before seeking care.\u003c\/p\u003e\n\u003cp\u003eShe had mild tenderness, no nipple discharge, and localized erythema (redness) and edema (swelling). She had no systemic symptoms.\u003c\/p\u003e\n\u003cp\u003eOn physical examination, her breasts were symmetric. A 4 cm × 3 cm firm mass was located laterally in the left breast. The mass had indistinct borders, limited mobility, and no tenderness when pressed.\u003c\/p\u003e\n\u003cp\u003eThe right breast had no palpable abnormalities, with convex nipples and no discharge. The axillary, clavicular, and cervical lymph nodes were unremarkable.\u003c\/p\u003e\n\u003cp\u003eSurgeons removed the left breast mass. The tissue showed histological features suggesting lymphomatous involvement. Examination of 3 left axillary sentinel lymph nodes (the first lymph nodes to which cancer would spread) showed no cancer infiltration.\u003c\/p\u003e\n\u003cp\u003eThe patient was then referred to Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, for comprehensive diagnostic evaluation. This included pathology, molecular profiling, bone marrow aspiration, and 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) imaging. Together, these tests confirmed the diagnosis of breast T-LBL.\u003c\/p\u003e\n\u003cp\u003eTreatment included 3 cycles of chemotherapy with additional nutritional and anti-infective support. Treatment also included a lumbar puncture with intrathecal therapy (medicine delivered directly into the spinal fluid). Treatment further included allogeneic stem cell transplantation (stem cells from a donor).\u003c\/p\u003e\n\u003cp\u003eFollow-up assessments, including bone marrow aspiration and 18F-FDG PET-CT scans, documented complete remission. The researchers created a schematic diagram to illustrate the patient's diagnostic and therapeutic journey.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging\"\u003eImaging Findings: Ultrasound, Mammography, MRI, and PET-CT\u003c\/h2\u003e\n\u003cp\u003eUltrasound of both breasts showed scattered hyperechoic strips (bright lines on the image) interconnected within the internal tissues, locally fused into a nodular configuration. A 4.1 cm × 3.8 cm × 2.0 cm heterogeneous hypoechoic lesion (a dark, mixed-texture area) was seen in the left lateral breast.\u003c\/p\u003e\n\u003cp\u003eThis lesion had poorly defined margins, irregular morphology, and grade I blood flow, with a resistivity index (RI) of 0.60. Elastography (an imaging method that measures tissue stiffness) showed a grade 4 lesion.\u003c\/p\u003e\n\u003cp\u003eIn the left axilla, elliptical hyperechoic structures measuring 1.1 cm × 0.8 cm and 0.9 cm × 0.7 cm with abundant medulla were identified. No significantly enlarged lymph nodes were seen in the right axilla, and no abnormal echoes appeared in the soft tissues of either axilla.\u003c\/p\u003e\n\u003cp\u003eOverall, the ultrasound findings indicated bilateral breast mastopathy (non-cancerous breast tissue changes). The ultrasound findings also indicated a left breast mass with an elastography grade of 4. The ultrasound findings further indicated a Breast Imaging Reporting and Data System (BI-RADS) category 0 on ultrasound. Lymph nodes were observed in the left axilla.\u003c\/p\u003e\n\u003cp\u003eMammographic imaging of both breasts revealed no notable masses.\u003c\/p\u003e\n\u003cp\u003eBreast magnetic resonance imaging (MRI) revealed an irregularly shaped mass measuring about 4.4 cm × 3.9 cm in the lateral quadrant of the left breast, with unclear borders. The mass showed isohigh signal intensity on T2-weighted images. The mass showed iso-signal on T1-weighted images. The mass showed high signal on diffusion-weighted imaging (DWI). The mass showed a low apparent diffusion coefficient (ADC) value of 0.58 × 10⁻³ mm²\/s.\u003c\/p\u003e\n\u003cp\u003eThe mass demonstrated heterogeneous enhancement after contrast and a plateau in the time-intensity curve (TIC) after enhancement.\u003c\/p\u003e\n\u003cp\u003eSimilarly, an irregularly shaped mass measuring around 2.0 cm × 2.3 cm with indistinct borders was detected in the inner lower quadrant of the right breast. This mass had an ADC value of 0.58 × 10⁻³ mm²\/s, uneven enhancement, and a plateau in the TIC.\u003c\/p\u003e\n\u003cp\u003eAnother irregularly shaped mass of similar characteristics, measuring about 2.0 cm × 2.3 cm, was observed in the lower quadrant of the right breast. Its MRI signal patterns, ADC values, enhancement patterns, and TIC curves matched those of the left breast mass.\u003c\/p\u003e\n\u003cp\u003eNo distinct abnormal masses or mass-like enhancements appeared in the remaining breast tissue on both sides. MRI designated the bilateral breast masses as BI-RADS 4B. There was no evidence of nipple or skin infiltration. Lymph nodes in the left axilla were visible within the imaging field but showed no signs of enlargement.\u003c\/p\u003e\n\u003cp\u003eBefore chemotherapy, 18F-FDG PET-CT showed postoperative changes in the left breast after resection, with no detectable FDG-avid lesions (areas of high metabolic activity that could indicate cancer). Slightly elevated metabolic activity appeared in the medial quadrant of the right breast, possibly due to normal physiological uptake.\u003c\/p\u003e\n\u003cp\u003eSeveral small lymph nodes in the left axilla, each measuring about 0.8 cm, showed increased metabolism with a maximum standardized uptake value (SUVmax) of about 5.1. These were initially considered inflammatory, and lymphoma infiltration was ruled out through close monitoring.\u003c\/p\u003e\n\u003cp\u003eAfter chemotherapy, 18F-FDG PET-CT showed diffuse and uniform elevation of metabolic activity in the central bone marrow, with an SUVmax of 2.9. This was considered likely due to reactive hyperplasia (a normal increase in bone marrow cell production). No conspicuous hypermetabolic lesions were observed anywhere in the body after treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"pathology\"\u003ePathology and Bone Marrow Results\u003c\/h2\u003e\n\u003cp\u003eAfter all required examinations were completed and contraindications to surgery were excluded, doctors established a clinical diagnosis. The diagnosis was stage IIA malignant tumor localized in the outer lower quadrant of the left breast (cT2N0M0).\u003c\/p\u003e\n\u003cp\u003eA left breast-conserving modified radical mastectomy was performed. Hematoxylin and eosin staining plus immunohistochemical (IHC) staining were conducted on 3-mm formalin-fixed, paraffin-embedded tissue sections.\u003c\/p\u003e\n\u003cp\u003eThe pathological diagnosis at the authors' facility indicated nodular infiltrative growth of lymphoid tissue in the left breast. The pathologists considered follicular lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma but could not definitively exclude these possibilities. They recommended referral to a specialized healthcare facility.\u003c\/p\u003e\n\u003cp\u003eExamination of the 3 anterior sentinel lymph nodes in the left axilla revealed no tumor tissue.\u003c\/p\u003e\n\u003cp\u003eFurther consultation with Shanghai Ruijin Hospital confirmed the pathologic diagnosis of T-lymphoblastoid lymphoma in the left breast.\u003c\/p\u003e\n\u003cp\u003eIHC analysis using a panel of antibodies revealed the following results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTdT: positive\u003c\/li\u003e\n  \u003cli\u003eMyeloperoxidase: sparse positive\u003c\/li\u003e\n  \u003cli\u003eCD117: partially positive\u003c\/li\u003e\n  \u003cli\u003eCD3: positive\u003c\/li\u003e\n  \u003cli\u003eCD5: positive\u003c\/li\u003e\n  \u003cli\u003eCD7: positive\u003c\/li\u003e\n  \u003cli\u003eCD10: positive\u003c\/li\u003e\n  \u003cli\u003eCD43: positive\u003c\/li\u003e\n  \u003cli\u003eC-MYC: about 80% positive\u003c\/li\u003e\n  \u003cli\u003eCD79a: weakly positive\u003c\/li\u003e\n  \u003cli\u003eBCL-2: positive\u003c\/li\u003e\n  \u003cli\u003eCD20: negative\u003c\/li\u003e\n  \u003cli\u003eBCL-6: negative\u003c\/li\u003e\n  \u003cli\u003eCyclinD1: negative\u003c\/li\u003e\n  \u003cli\u003eSOX-11: negative\u003c\/li\u003e\n  \u003cli\u003eIgD: negative\u003c\/li\u003e\n  \u003cli\u003eMUM-1: negative\u003c\/li\u003e\n  \u003cli\u003eKappa: negative\u003c\/li\u003e\n  \u003cli\u003eLambda: negative\u003c\/li\u003e\n  \u003cli\u003eCD56: negative\u003c\/li\u003e\n  \u003cli\u003eCD4: negative\u003c\/li\u003e\n  \u003cli\u003eCD2: negative\u003c\/li\u003e\n  \u003cli\u003eCD8: negative\u003c\/li\u003e\n  \u003cli\u003eCD34: negative\u003c\/li\u003e\n  \u003cli\u003eP53: about 95% positive, moderate intensity\u003c\/li\u003e\n  \u003cli\u003eCD21 (follicular dendritic cell marker): positive\u003c\/li\u003e\n  \u003cli\u003eCD23 (follicular dendritic cell marker): positive\u003c\/li\u003e\n  \u003cli\u003eProgrammed death-ligand 1 (combined positive score, CPS): less than 1\u003c\/li\u003e\n  \u003cli\u003eKi67: about 85% positive\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn situ hybridization for Epstein-Barr virus Encoded RNA was negative. Evaluation of the left axillary lymph nodes revealed no concerning findings.\u003c\/p\u003e\n\u003cp\u003eFluorescence in situ hybridization analysis using the MALT1(18q21) breakage probe, BIRC3\/MALT1 fusion probe, and TP53(17p13) deletion probe was negative.\u003c\/p\u003e\n\u003cp\u003eA bone marrow biopsy showed essentially normal hematopoietic cell proliferation across the 3 lineages, with no evident heterogeneous component.\u003c\/p\u003e\n\u003cp\u003eA comprehensive genetic screening covering 84 genes for peripheral T-lineage lymphoma did not reveal any clinically significant genetic variants.\u003c\/p\u003e\n\n\u003ch2 id=\"literature\"\u003eWhat the Literature Review Found Across 11 Patients\u003c\/h2\u003e\n\u003cp\u003eThe study included a total of 11 cases. Six cases with comprehensive clinical data came from English literature, 4 cases came from Chinese literature, and 1 case came from the authors' own research.\u003c\/p\u003e\n\u003cp\u003eAll 11 patients were female, with an average age of 31.81 ± 11.97 years.\u003c\/p\u003e\n\u003cp\u003eFive cases involved both breasts, while the remaining 6 involved one breast. The unilateral cases were divided equally between the left and right breasts.\u003c\/p\u003e\n\u003cp\u003eOne case involved only the breast. Ten cases showed extramammary infiltration (cancer spread beyond the breast), including 3 instances confined to the axillary lymph nodes.\u003c\/p\u003e\n\u003cp\u003eIHC evaluation revealed positivity for both TdT and CD3 in 9 cases with breast lesions. Five cases showed evidence of bone marrow infiltration.\u003c\/p\u003e\n\u003cp\u003eImaging use across the cases was as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eUltrasound: 6 cases\u003c\/li\u003e\n  \u003cli\u003eMammography: 6 cases\u003c\/li\u003e\n  \u003cli\u003eMRI: 1 case\u003c\/li\u003e\n  \u003cli\u003ePET-CT: 2 cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe breast masses had a maximum diameter ranging from approximately 1.7 cm to 4.4 cm.\u003c\/p\u003e\n\u003cp\u003eTreatment strategies centered predominantly on various forms of chemotherapy. These included 4 cases using the Cyclophosphamide, Doxorubicin, Vincristine, Prednisone regimen, 3 cases using the Hype-CVAD protocol, 3 cases using other variants, and 1 case using an unspecified approach.\u003c\/p\u003e\n\u003cp\u003eSome cases received combined radiotherapy and chemotherapy. Certain cases also received a combination of radiotherapy and intrathecal drug therapy to prevent central nervous system infiltration.\u003c\/p\u003e\n\n\u003ch2 id=\"discussion\"\u003eDiscussion: Diagnosis, Biology, and Behavior of Breast T-LBL\u003c\/h2\u003e\n\u003cp\u003eBreast lymphoma is a rare hematological neoplasm (blood cancer) that arises from lymphoid tissue within the breast. Its estimated incidence ranges from about 0.04% to 0.7%.\u003c\/p\u003e\n\u003cp\u003eBreast lymphomas are predominantly classified as non-Hodgkin's lymphoma. The scarcity of breast lymphomas may be explained by the relatively limited presence of lymphoid tissue in this anatomical site.\u003c\/p\u003e\n\u003cp\u003eT-cell lymphoblastoid lymphoma (LBL) is a subset of non-Hodgkin's lymphoma characterized by high aggressiveness. It primarily affects adolescents and young males.\u003c\/p\u003e\n\u003cp\u003eT-LBL constitutes around 3% to 4% of non-Hodgkin's lymphomas in adults and about 40% of cases in pediatric populations. It often exhibits mediastinal and bone marrow infiltration.\u003c\/p\u003e\n\u003cp\u003eThis entity is known for its aggressive behavior, malignancy, and heterogeneity (variability). It typically originates from immature precursor T lymphocytes. T-LBL presenting in the breast is exceedingly rare, which underscores the unique nature of this pathological entity.\u003c\/p\u003e\n\u003cp\u003eBreast T-LBL is typically diagnosed through biopsy or postoperative pathology. The cancer is characterized by medium-sized lymphoblasts with round, oval, or convoluted nuclei. The cancer is characterized by finely dispersed nuclear chromatin, inconspicuous or small nucleoli, and scanty basophilic cytoplasm. The cancer is characterized by frequent mitoses (cell divisions) and regions of necrosis (dead tissue).\u003c\/p\u003e\n\u003cp\u003eDistinguishing T-LBL from B-lymphoblastic lymphoma requires immunophenotypic analysis.\u003c\/p\u003e\n\u003cp\u003eThis lymphoma subtype is predominantly of T-lymphoblastic origin, comprising about 80% of cases. It commonly shows positivity for TdT, CD3, and CD7 in 90% of instances. About half of cases show dual positivity for CD4 and CD8. CD10, CD34, CD1a, and CD99 are also frequently expressed.\u003c\/p\u003e\n\u003cp\u003eThe authors' investigation challenges prior notions about the sidedness of breast lymphomas. It reveals a predominant bilaterality in cases of T-lymphoblastoid lymphomas. Bilateral involvement is linked to the notably aggressive nature of this disease.\u003c\/p\u003e\n\u003cp\u003eBecause these lymphomas can involve the mediastinum, they are often associated with pericardial or pleural effusions (fluid around the heart or lungs). This makes thoracic imaging crucial for assessing mediastinal mass presence and evaluating the risk of pericardial tamponade (compression of the heart by fluid).\u003c\/p\u003e\n\u003cp\u003eInfiltration of peripheral lymph nodes, particularly cervical nodes, is common. Central nervous system involvement is relatively infrequent, occurring in less than 5% of patients.\u003c\/p\u003e\n\u003cp\u003eBone marrow invasion is observed in about 15% to 20% of cases. It is typically characterized by active or markedly active bone marrow nucleated cell hyperplasia with primitive cell hyperplasia, although this occurs in less than a quarter of cases.\u003c\/p\u003e\n\u003cp\u003eUsing multiparametric flow cytometry (a technique that analyzes individual cells), T-LBL typically shows expression of T-cell specific markers such as CD3. It often also exhibits CD38, CD7, CD99, and cTdT markers.\u003c\/p\u003e\n\n\u003ch2 id=\"molecular\"\u003eMolecular and Genetic Features\u003c\/h2\u003e\n\u003cp\u003eWith the rapid advancement of detection methodologies, exploration of the molecular underpinnings of T-LBL has progressed from the cellular level to the genetic level.\u003c\/p\u003e\n\u003cp\u003eResearchers have identified various genetic abnormalities in T-LBL. These include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAntigen receptor gene rearrangements, such as clonal rearrangement of TCRαβ chain genes\u003c\/li\u003e\n  \u003cli\u003eChromosomal aberrations, such as translocations, deletions, and rearrangements\u003c\/li\u003e\n  \u003cli\u003eOncogene inactivation, involving genes such as PTEN, FBXW7, and BIM\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn the authors' own patient, genetic screening of 84 genes for peripheral T-lineage lymphoma did not reveal any clinically significant genetic variants. Fluorescence in situ hybridization probes for MALT1, BIRC3\/MALT1, and TP53 were also negative.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\u003cp\u003eBreast T-LBL is exceedingly rare, and accurate diagnosis is crucial for management. This is the central message of the study.\u003c\/p\u003e\n\u003cp\u003eBecause the disease is so uncommon, it can be mistaken for other conditions. In the authors' patient, the initial pathology report at their facility suggested follicular lymphoma or MALT lymphoma and could not definitively exclude those possibilities. Only after referral to a specialized center was the correct diagnosis of T-lymphoblastoid lymphoma confirmed.\u003c\/p\u003e\n\u003cp\u003eThis case illustrates that specialized pathology review and a full panel of immunohistochemical markers are essential. The correct diagnosis depended on markers such as TdT, CD3, CD7, CD10, and others.\u003c\/p\u003e\n\u003cp\u003eThe study also found that breast T-LBL often affects both breasts. Five of the 11 patients had bilateral involvement. This bilateral pattern is linked to the aggressive nature of the disease.\u003c\/p\u003e\n\u003cp\u003eMost patients in the review (10 of 11) had cancer that had spread beyond the breast. This finding highlights that breast T-LBL is usually not confined to the breast at diagnosis.\u003c\/p\u003e\n\u003cp\u003eTreatment in the reviewed cases centered on chemotherapy. Ten of the 11 patients received chemotherapy, with some also receiving radiotherapy and intrathecal prophylaxis (preventive treatment delivered into the spinal fluid) to protect against central nervous system spread.\u003c\/p\u003e\n\u003cp\u003eThe authors' own patient received 3 cycles of chemotherapy, intrathecal therapy, and allogeneic stem cell transplantation. Follow-up bone marrow aspiration and PET-CT scans documented complete remission.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Study\u003c\/h2\u003e\n\u003cp\u003eThis study is a retrospective observational study, meaning it looked back at existing records rather than following patients forward in time. This design limits the strength of the conclusions that can be drawn.\u003c\/p\u003e\n\u003cp\u003eThe total number of patients was very small — only 11 cases, including the authors' own patient. Six cases came from English literature, 4 from Chinese literature, and 1 from the authors' research.\u003c\/p\u003e\n\u003cp\u003eBecause the disease is so rare, no prospective studies or clinical trials were available to guide diagnosis and treatment. The treatment approaches described varied widely across the 11 cases, which makes it difficult to compare outcomes.\u003c\/p\u003e\n\u003cp\u003eThe authors state directly that future prospective studies are needed to optimize diagnostic and therapeutic strategies for breast T-LBL.\u003c\/p\u003e\n\u003cp\u003eThe study also notes that the rarity of breast lymphomas may be related to the limited amount of lymphoid tissue in the breast. However, this remains an observation rather than a proven mechanism.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Take-Home Points\u003c\/h2\u003e\n\u003cp\u003eFor patients and clinicians, the study offers several practical points:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eBreast T-LBL is extremely rare. In the authors' patient, the mass had indistinct borders, limited mobility, and no tenderness. The authors conclude that when MRI identifies single or multiple breast masses with low ADC values and type II or III enhancement curves in both breasts, a puncture biopsy should be recommended to avoid misdiagnosis as breast cancer.\u003c\/li\u003e\n  \u003cli\u003eAccurate diagnosis requires a full panel of immunohistochemical markers. Key markers include TdT, CD3, and CD7, which were positive in 9 of the breast lesions reviewed.\u003c\/li\u003e\n  \u003cli\u003eReferral to a specialized center may be needed. In the authors' case, the initial diagnosis was uncertain until a specialized hospital confirmed T-lymphoblastoid lymphoma.\u003c\/li\u003e\n  \u003cli\u003eImaging plays an important role. Ultrasound, mammography, MRI, and PET-CT were all used across the reviewed cases. MRI in the authors' patient showed low ADC values (0.58 × 10⁻³ mm²\/s) and plateau TIC curves in both breasts.\u003c\/li\u003e\n  \u003cli\u003eTreatment typically involves chemotherapy. Ten of 11 patients received chemotherapy, and some also received radiotherapy and intrathecal prophylaxis.\u003c\/li\u003e\n  \u003cli\u003eBone marrow evaluation is important. Five of the reviewed cases showed bone marrow infiltration, and bone marrow invasion is reported in about 15% to 20% of T-LBL cases.\u003c\/li\u003e\n  \u003cli\u003eCentral nervous system involvement is uncommon but possible. It occurs in less than 5% of patients, which is why some patients receive intrathecal preventive therapy.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe authors emphasize that breast T-LBL is exceedingly rare and that accurate diagnosis is crucial for management. They call for future prospective studies to optimize diagnostic and therapeutic strategies.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is T-cell lymphoblastic lymphoma of the breast?\u003c\/h3\u003e\n\u003cp\u003eIt is an extremely rare and aggressive cancer that starts in early immune cells called lymphoblasts and appears in breast tissue. In a review of 11 female patients, 5 had tumors in both breasts and 6 in one breast, and 10 of the 11 had cancer spread beyond the breast. Accurate diagnosis is essential.\u003c\/p\u003e\n\u003ch3\u003eHow is breast T-cell lymphoblastic lymphoma diagnosed?\u003c\/h3\u003e\n\u003cp\u003eDiagnosis is made through biopsy or tissue removed during surgery, using a full panel of immunohistochemical markers. In the reviewed cases, 9 breast lesions were positive for both TdT and CD3. Because the disease is so uncommon, it can be mistaken for other lymphomas, so referral to a specialized center may be needed.\u003c\/p\u003e\n\u003ch3\u003eWhat imaging tests were used for breast T-cell lymphoblastic lymphoma?\u003c\/h3\u003e\n\u003cp\u003eAcross the reviewed cases, ultrasound was used in 6, mammography in 6, MRI in 1, and PET-CT in 2. In one patient, MRI showed low ADC values of 0.58 × 10⁻³ mm²\/s and plateau time-intensity curves in both breasts. Imaging helps assess the breast and whether the cancer has spread.\u003c\/p\u003e\n\u003ch3\u003eHow is breast T-cell lymphoblastic lymphoma treated?\u003c\/h3\u003e\n\u003cp\u003eTreatment in the reviewed cases centered on chemotherapy: 10 of 11 patients received it, and some also had radiotherapy and intrathecal prophylaxis, which is preventive treatment delivered into the spinal fluid. One patient received 3 cycles of chemotherapy, intrathecal therapy, and allogeneic stem cell transplantation, and follow-up documented complete remission.\u003c\/p\u003e\n\u003ch3\u003eDoes breast T-cell lymphoblastic lymphoma spread to the bone marrow or nervous system?\u003c\/h3\u003e\n\u003cp\u003eIn the reviewed cases, 5 of 11 showed bone marrow infiltration. Bone marrow invasion is reported in about 15% to 20% of T-LBL cases. Central nervous system involvement is relatively infrequent, occurring in less than 5% of patients, which is why some patients receive intrathecal preventive therapy. Bone marrow evaluation is important.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean if a breast mass has indistinct borders and limited mobility?\u003c\/h3\u003e\n\u003cp\u003eIn one patient with breast T-cell lymphoblastic lymphoma, the mass had indistinct borders, limited mobility, and no tenderness. Such unusual features should prompt consideration of this rare cancer. However, these findings alone do not confirm the diagnosis, which requires tissue examination and a full panel of immunohistochemical markers.\u003c\/p\u003e\n\u003ch3\u003eAre there genetic changes in breast T-cell lymphoblastic lymphoma?\u003c\/h3\u003e\n\u003cp\u003eVarious genetic abnormalities have been identified in T-LBL, including antigen receptor gene rearrangements, chromosomal aberrations, and oncogene inactivation involving genes such as PTEN, FBXW7, and BIM. In one patient, genetic screening of 84 genes for peripheral T-lineage lymphoma did not reveal any clinically significant variants, and FISH probes for MALT1, BIRC3\/MALT1, and TP53 were negative.\u003c\/p\u003e\n\u003ch3\u003eI was told I have T-cell lymphoblastic lymphoma of the breast — when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth seeking when a breast mass has unusual features, such as indistinct borders, limited mobility, and no tenderness. Breast T-LBL is exceedingly rare and can be mistaken for follicular lymphoma or MALT lymphoma; in one reported case the correct diagnosis was confirmed only after referral to a specialized center. Accurate diagnosis requires a full panel of immunohistochemical markers, including TdT, CD3, and CD7. Because treatment centers on chemotherapy, with some patients also receiving radiotherapy and intrathecal prophylaxis, confirming the diagnosis first matters. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e T-cell lymphoblastic lymphoma of the breast: A retrospective observational study and literature review.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Wei Bian, Jun Yuan, Yufeng Fei, Jinjuan Feng, Xu Zhang, Sili Jin, and Yi Yang\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Medicine, 2026;105:11(e47991)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e http:\/\/dx.doi.org\/10.1097\/MD.0000000000047991\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The research was funded by the Livelihood Science and Technology Innovation Research project under the Jiaxing Science and Technology Plan (Grant numbers: 2022AD30095 and 2025CGW064).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics:\u003c\/strong\u003e The studies involving human participants were reviewed and approved by the Ethical Committee of Jiaxing Maternity and Child Health Care Hospital. Informed written consent was obtained from the patient for publication of this case report and any accompanying images.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47807364006044,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/da\/products\/t-cell-lymphoblastic-lymphoma-of-the-breast-what-a-rare-cancer-study-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}